CAR T-cell therapy and immunotherapy in general has shown great promise. Continued funding and research can lead to fine-tuning of drug therapies as well as targets for different kinds of cancers. Immunotherapy at this point should not be looked at as a ‘silver bullet’ to cure cancer, however it can be another tool that oncologists can use to improve standard of living and remission length.
Recent comments